Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carvedilol controlled release - RedHill Biopharma

X
Drug Profile

Carvedilol controlled release - RedHill Biopharma

Alternative Names: Cardio; EG-P042; RHB-101

Latest Information Update: 07 Jan 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Egalet
  • Developer RedHill Biopharma
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Heart failure; Hypertension; Left ventricular dysfunction

Most Recent Events

  • 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics
  • 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Heart-failure in Israel (PO, Controlled release)
  • 28 Jan 2019 No recent reports of development identified for clinical-Phase-Unknown development in Hypertension in Israel (PO, Controlled release)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top